Connor, Clark & Lunn Investment Management (CC&L)
KALV

Connor, Clark & Lunn Investment Management (CC&L)’s KalVista Pharmaceuticals KALV Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,949
Closed -$266K – 1516
2024
Q3 		$266K Buy
22,949
+12,245
+114% +$154K ﹤0.01% 1275
2024
Q2 		$126K Sell
10,704
-57,501
-84% -$671K ﹤0.01% 1298
2024
Q1 		$809K Sell
68,205
-42,717
-39% -$570K ﹤0.01% 945
2023
Q4 		$1.36M Buy
110,922
+6,254
+6% +$56.9K 0.01% 770
2023
Q3 		$1.01M Sell
104,668
-3,307
-3% -$33.8K 0.01% 812
2023
Q2 		$972K Buy
107,975
+8,104
+8% +$74.7K ﹤0.01% 803
2023
Q1 		$785K Buy
99,871
+6,458
+7% +$48.2K ﹤0.01% 779
2022
Q4 		$631K Sell
93,413
-2,173
-2% -$11.6K ﹤0.01% 815
2022
Q3 		$1.39M Buy
95,586
+29,704
+45% +$415K 0.01% 578
2022
Q2 		$648K Buy
65,882
+42,989
+188% +$474K ﹤0.01% 718
2022
Q1 		$337K Buy
22,893
+6,845
+43% +$98.3K ﹤0.01% 850
2021
Q4 		$212K Buy
16,048
+4,161
+35% +$66.2K ﹤0.01% 965
2021
Q3 		$207K Buy
+11,887
New +$241K ﹤0.01% 941

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s KALV Position: Q4 2024 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of KalVista Pharmaceuticals (KALV) in Q4 2024, closing a stake of 22,949 shares — an estimated $266K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KALV in Q3 2021 and held it in 13 quarters. The position peaked at $1.39M in Q3 2022. 130 funds tracked by Wall St. Rank hold KALV as of Q4 2024.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining KalVista Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 22,949 KalVista Pharmaceuticals shares in Q4 2024, an estimated $266K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in KalVista Pharmaceuticals in Q3 2021 and held it in 13 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s KalVista Pharmaceuticals position peaked at $1.39M in Q3 2022.
  • 130 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2024.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2024, filed 10 Feb 2025.